A groundbreaking study published in the journal Genes has fundamentally altered the scientific
The burgeoning market for GLP-1 weight-loss medications created a gold rush for telehealth
With a deep background in biopharmaceutical research and development, Ivan Kairatov has a keen eye for innovations that could reshape how we treat the most challenging cancers. Today, he joins us to discuss a promising new preclinical study on pancreatic ductal adenocarcinoma (PDAC), a notoriously
The emergence of cell-cultured protein has sparked intense debate at the intersection of agricultural tradition and technological innovation, nowhere more so than in states with deep roots in the livestock industry. In South Dakota, a legislative effort to completely prohibit the sale of lab-grown
We're joined today by Biopharma expert Ivan Kairatov, whose work sits at the intersection of
The immense complexity of the human brain, mirrored in the subtle and highly variable details of
The biopharmaceutical sector is entering a new era. After last year's market disruptions, the industry faces a harsh truth: scientific breakthroughs alone are no longer enough to keep ahead of the…
By 2030, the tissue-engineering market is projected to exceed $32.45 billion , reflecting a
The landscape of rare disease drug development is littered with clinical failures. For every
Major policy changes are colliding with the complex economics of drug development. For B2B
Biopharma companies have always operated at the edge of uncertainty. Scientific discovery is
In the landscape of neurodegenerative diseases, the battle is often fought against uncertainty as much as the condition itself. For those living with Motor Neurone Disease (MND), the unpredictable progression can make planning for critical interventions, like the placement of a feeding tube, an
The ability to precisely visualize and manipulate molecular machinery inside living cells has long
The seamless integration of advanced robotics with the human body represents a monumental leap in
